SGLT2 inhibitors are a key component of guideline-directed therapy for CKD. This Review examines SGLT2 inhibitors’ role in tubuloglomerular feedback and summarizes emerging evidence on SGLT2 inhibitors’ putative mechanisms for kidney protection bit.ly/KID00425

On the #AJKDBlog: Timothy Yau talks to Alex Chang, MD, FASN, FAHA and Evan Zeitler about prescribing practices as a practical tool to engage nephrologists and patients with CKD in the treatment of obesity-related morbidity: buff.ly/41D1chr

Celebrating milestones and forging futures at Granite Links! Congrats to our 4 outstanding fellows on their graduation from the Boston Medical Center Nephrology Fellowship Program. Here's to the next chapter of excellence in kidney care! #BMCNephrology #GraduationCelebration 🎉

Our design & baseline paper for the FIND-CKD trial now out in NDT: Finerenone vs placebo in non-diabetic CKD N=1584 57% GN (417 with IgAN) Mean eGFR 46 Median UACR 819mg/g 17% SGLT2i use at baseline Primary outcome: total slope over 32 months academic.oup.com/ndt/article/do…

Adults undergoing cardiac surgery with cardiopulmonary bypass received either an intravenous balanced mixture of amino acids or placebo for up to 3 days. Amino acids reduced the occurrence of acute kidney injury. Full PROTECTION trial results: nej.md/45zYDyF #CCR24

Really great thread - captures precisely what I tell junior faculty w academic aspirations (& says it better than I do!) I also tell them that many faculty ultimately focus on being a great clinician & having robust life outside of career, & that our section celebrates that too

The legendary GL Bakris, 700+ papers on PubMed, more importantly, cited almost 250,000 times. Sat at his table a few times during conferences. A delight to listen to what he had to say. Utmost respect. R.I.P. George Bakris

I am deeply moved to announce that my review article on AL amyloidosis is published in the NEJM on June 27. This date marks the death anniversary of my mentor, Dr. David Seldin, whose guidance was instrumental in my journey. BU Amyloidosis Center nejm.org/doi/full/10.10…

Goodbye to our amazing outpatient dialysis dietician after 20 years of service

Exciting start to our 3 day POCUS training today in the SIM lab Boston Medical Center ! Drs. Jaberi and Gunasekaran led a hands-on session, immersing our first-year fellows in Renal US. #bmc #POCUS #renalUS #medicaltraining #bostonmedicalcenter #nephrology #fellows

Another exciting day in IgA Nephropathy novartis.com/news/media-rel…

BU/BMC Section of Nephrology faculty, Dr titi ilori, Dr. Afolarin Amodu and team joined community members YMCA Greater Boston Roxbury to teach and talk about kidney health. Boston Medical Center BU/BMC IM Residency Boston U Chobanian & Avedisian School of Medicine

Read our newly minted renal fellow Santhoshi Bavi MD 🇮🇳🇺🇸 and mentor Katie Rizzolo’s views on equitable access to transplantation for non-citizens and their take on OPTN and transplant-center level policies. #HealthEquity #transplant link.springer.com/article/10.100…

Our researchers Insa Marie Schmidt Sophie Claudel, MD Ashish Verma Sushrut Waikar and Kidney Precision Medicine Project collaborators identify plasma biomarkers associated with acute tubular injury severity using plasma proteomics technology. Read the full article here at Nature Communications nature.com/articles/s4146…

The KDIGO 2024 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV) is available for public review through Monday, September 30. You can download the public review draft and share comments via the feedback survey on the KDIGO

🎉 Huge congratulations to our second-year fellow Joyita Bharati for being honored as CJASN Reviewer of the Year! Your commitment to academic rigor through fellowship is commendable! #nephX #nephtwitter

Congratulations to our second year fellow, Aditya Ragunathan, for being awarded the ASN ASN Kidney News travel grant to participate at CRRT_Academy.

Wait torsemide has less kidney bioavailability than furosemide and the appropriate PO ratio between them is actually 4:1? 🤯 journals.lww.com/jasn/pages/art…

Judy Faulkner is the billionaire founder of Epic Systems, and a recent study by Dr. Christine Sinsky reveals the following time spent on Epic per 8 hours seeing patients: • Infectious Disease 8.4 Hours • Endocrinology 7.7 Hours • Nephrology 7.5 Hours • Primary Care 7.3 Hours

End of our summer point-of-care ultrasound boot camp for renal fellows led by in-house #POCUS faculty champions Aala Jaberi and Deepthi Gunasekaran. On to more scanning on the wards Boston Medical Center for volume assessment! #MedEd MikeBaldino Rivka Ayalon Ashish Upadhyay